AlphaMadera's AlphaVal page computes Recursion Pharmaceuticals, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag RXRX as undervalued, fairly valued, or overvalued.

What is Recursion Pharmaceuticals, Inc.'s fair value?

Fair value for RXRX is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value RXRX?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from RXRX's most recent reported fundamentals.

RXRX - Recursion Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $5.50 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: RXRX has had negative net income and negative EPS in all 5 available fiscal year(s). Quality gate: persistently unprofitable companies are excluded.